Myc pathway-guided alternative splicing events predict the overall survival of lung squamous cell carcinoma

References

• Aloia L, Demajo S, Di Croce L. 2015. ZRF1: a novel epigenetic regulator of stem cell identity and cancer. Cell Cycle. 14:510–515.
   PubMed Web of Science ®Google Scholar
• Avery-Kiejda KA, Morten B, Wong-Brown MW, Mathe A, Scott RJ. 2014. The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome. Carcinogenesis. 35:586–596.
   PubMed Web of Science ®Google Scholar
• Battistelli S, Stefanoni M, Lorenzi B, Dell’avanzato R, Varrone F, Pascucci A, Petrioli R, Vittoria V. 2008. Coagulation factor levels in non-metastatic colorectal cancer patients. Int J Biol Markers. 23:36–41.
   Web of Science ®Google Scholar
• Bonnal SC, Lopez-Oreja I, Valcarcel J. 2020. Roles and mechanisms of alternative splicing in cancer – implications for care. Nat Rev Clin Oncol. 17:457–474.
   PubMed Web of Science ®Google Scholar
• Chanvorachote P, Sriratanasak N, Nonpanya N. 2020. C-myc contributes to malignancy of lung cancer: a potential anticancer drug target. Anticancer Res. 40:609–618.
   PubMed Web of Science ®Google Scholar
• Chen L, Yao Y, Sun L, Zhou J, Miao M, Luo S, Deng G, Li J, Wang J, Tang J. 2017. Snail driving alternative splicing of CD44 by ESRP1 enhances invasion and migration in epithelial ovarian cancer. Cell Physiol Biochem. 43:2489–2504.
   PubMedGoogle Scholar
• Chen P, He J, Ye H, Jiang S, Li Y, Li X, Wan J. 2020. Comprehensive analysis of prognostic alternative splicing signatures in endometrial cancer. Front Genet. 11:456.
   PubMed Web of Science ®Google Scholar
• Du JX, Liu YL, Zhu GQ, Luo YH, Chen C, Cai CZ, Zhang SJ, Wang B, Cai JL, Zhou J, et al. 2021. Profiles of alternative splicing landscape in breast cancer and their clinical significance: an integrative analysis based on large-sequencing data. Ann Transl Med. 9:58.
   PubMed Web of Science ®Google Scholar
• Farina AR, Cappabianca L, Sebastiano M, Zelli V, Guadagni S, Mackay AR. 2020. Hypoxia-induced alternative splicing: the 11th hallmark of cancer. J Exp Clin Cancer Res. 39:110.
   PubMed Web of Science ®Google Scholar
• Garcia-Blanco MA, Baraniak AP, Lasda EL. 2004. Alternative splicing in disease and therapy. Nat Biotechnol. 22:535–546.
   PubMed Web of Science ®Google Scholar
• Genova C, Rijavec E, Grossi F. 2016. Recent advances in squamous non-small cell lung cancer: evidence beyond predictive biomarkers. Expert Rev Anticancer Ther. 16:1–4.
   PubMed Web of Science ®Google Scholar
• Ghigna C, Giordano S, Shen H, Benvenuto F, Castiglioni F, Comoglio PM, Green MR, Riva S, Biamonti G. 2005. Cell motility is controlled by SF2/ASF through alternative splicing of the Ron protooncogene. Mol Cell. 20:881–890.
   PubMed Web of Science ®Google Scholar
• Hu YX, Zheng MJ, Zhang WC, Li X, Gou R, Nie X, Liu Q, Hao YY, Liu JJ, Lin B. 2019. Systematic profiling of alternative splicing signature reveals prognostic predictor for cervical cancer. J Transl Med. 17:379.
   PubMed Web of Science ®Google Scholar
• Kalam H, Fontana MF, Kumar D, Salgame P. 2017. Alternate splicing of transcripts shape macrophage response to mycobacterium tuberculosis infection. PLoS Pathog. 13:e1006236.
   PubMed Web of Science ®Google Scholar
• Kelemen O, Convertini P, Zhang Z, Wen Y, Shen M, Falaleeva M, Stamm S. 2013. Function of alternative splicing. Gene. 514:1–30.
   PubMed Web of Science ®Google Scholar
• Kim E, Goren A, Ast G. 2008. Alternative splicing: current perspectives. Bioessays. 30:38–47.
   PubMed Web of Science ®Google Scholar
• Koh CM, Bezzi M, Low DH, Ang WX, Teo SX, Gay FP, Al-Haddawi M, Tan SY, Osato M, Sabo A, et al. 2015. MYC regulates the core pre-mRNA splicing machinery as an essential step in lymphomagenesis. Nature. 523:96–100.
   PubMed Web of Science ®Google Scholar
• Kornblihtt AR, Schor IE, Allo M, Dujardin G, Petrillo E, Munoz MJ. 2013. Alternative splicing: a pivotal step between eukaryotic transcription and translation. Nat Rev Mol Cell Biol. 14:153–165.
   PubMed Web of Science ®Google Scholar
• Ladomery M. 2013. Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol. 2013:1–6.
   Google Scholar
• Letourneux C, Rocher G, Porteu F. 2006. B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J. 25:727–738.
   PubMed Web of Science ®Google Scholar
• Li HH, Cai X, Shouse GP, Piluso LG, Liu X. 2007. A specific PP2A regulatory subunit, B56gamma, mediates DNA damage-induced dephosphorylation of p53 at Thr55. EMBO J. 26:402–411.
   PubMed Web of Science ®Google Scholar
• Liang T, Sang S, Shao Q, Chen C, Deng Z, Wang T, Kang Q. 2020. Abnormal expression and prognostic significance of EPB41L1 in kidney renal clear cell carcinoma based on data mining. Cancer Cell Int. 20:356.
   PubMed Web of Science ®Google Scholar
• Liao Y, Xiao H, Cheng M, Fan X. 2020. Bioinformatics analysis reveals biomarkers with cancer stem cell characteristics in lung squamous cell carcinoma. Front Genet. 11:427.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Subramanian A, Pinchback R, Thorvaldsdottir H, Tamayo P, Mesirov JP. 2011. Molecular signatures database (MSigDB) 3.0. Bioinformatics. 27:1739–1740.
   PubMed Web of Science ®Google Scholar
• Lin P, He RQ, Ma FC, Liang L, He Y, Yang H, Dang YW, Chen G. 2018. Systematic analysis of survival-associated alternative splicing signatures in gastrointestinal pan-adenocarcinomas. EBioMedicine. 34:46–60.
   PubMed Web of Science ®Google Scholar
• Liu Y, Jia W, Li J, Zhu H, Yu J. 2020. Identification of survival-associated alternative splicing signatures in lung squamous cell carcinoma. Front Oncol. 10:587343.
   PubMed Web of Science ®Google Scholar
• Liu YS, Luo XY, Li QR, Li H, Li C, Ni H, Li RX, Wang R, Hu HC, Pan YJ, et al. 2012. Shotgun and targeted proteomics reveal that pre-surgery serum levels of LRG1, SAA, and C4BP may refine prognosis of resected squamous cell lung cancer. J Mol Cell Biol. 4:344–347.
   PubMed Web of Science ®Google Scholar
• Marzese DM, Manughian-Peter AO, Orozco JIJ, Hoon DSB. 2018. Alternative splicing and cancer metastasis: prognostic and therapeutic applications. Clin Exp Metastasis. 35:393–402.
   PubMed Web of Science ®Google Scholar
• Phillips JW, Pan Y, Tsai BL, Xie Z, Demirdjian L, Xiao W, Yang HT, Zhang Y, Lin CH, Cheng D, et al. 2020. Pathway-guided analysis identifies Myc-dependent alternative pre-mRNA splicing in aggressive prostate cancers. Proc Natl Acad Sci USA. 117:5269–5279.
   PubMed Web of Science ®Google Scholar
• Piva F, Giulietti M, Burini AB, Principato G. 2012. Spliceaid 2: a database of human splicing factors expression data and RNA target motifs. Hum Mutat. 33:81–85.
   PubMed Web of Science ®Google Scholar
• Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, et al. 2011. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 480:387–390.
   PubMed Web of Science ®Google Scholar
• Relli V, Trerotola M, Guerra E, Alberti S. 2019. Abandoning the notion of non-small cell lung cancer. Trends Mol Med. 25(7):585–594.
   PubMed Web of Science ®Google Scholar
• Ryan MC, Cleland J, Kim R, Wong WC, Weinstein JN. 2012. Spliceseq: a resource for analysis and visualization of RNA-Seq data on alternative splicing and its functional impacts. Bioinformatics. 28:2385–2387.
   PubMed Web of Science ®Google Scholar
• Sciarrillo R, Wojtuszkiewicz A, Assaraf YG, Jansen G, Kaspers GJL, Giovannetti E, Cloos J. 2020. The role of alternative splicing in cancer: from oncogenesis to drug resistance. Drug Resist Updat. 53:100728.
   PubMed Web of Science ®Google Scholar
• Scotti MM, Swanson MS. 2016. RNA mis-splicing in disease. Nat Rev Genet. 17:19–32.
   PubMed Web of Science ®Google Scholar
• Sebestyen E, Zawisza M, Eyras E. 2015. Detection of recurrent alternative splicing switches in tumor samples reveals novel signatures of cancer. Nucleic Acids Res. 43:1345–1356.
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, Amin N, Schwikowski B, Ideker T. 2003. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13:2498–2504.
   PubMed Web of Science ®Google Scholar
• Shouse GP, Cai X, Liu X. 2008. Serine 15 phosphorylation of p53 directs its interaction with B56gamma and the tumor suppressor activity of B56gamma-specific protein phosphatase 2A. Mol Cell Biol. 28:448–456.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Jemal A. 2019. Cancer statistics, 2019. Cancer J Clin. 69:7–34.
   PubMed Web of Science ®Google Scholar
• Song J, Liu YD, Su J, Yuan D, Sun F, Zhu J. 2019. Systematic analysis of alternative splicing signature unveils prognostic predictor for kidney renal clear cell carcinoma. J Cell Physiol. 234:22753–22764.
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. 2021. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Cancer J Clin. 71:209–249.
   PubMed Web of Science ®Google Scholar
• Tachibana K, Yamasaki D, Ishimoto K, Doi T. 2008. The role of PPARs in cancer. PPAR Res. 2008:102737.
   PubMed Web of Science ®Google Scholar
• Wan Q, Sang X, Jin L, Wang Z. 2020. Alternative splicing events as indicators for the prognosis of uveal melanoma. Genes (Basel). 11(2):227.
   Web of Science ®Google Scholar
• Wang E, Aifantis I. 2020. RNA splicing and cancer. Trends Cancer. 6:631–644.
   PubMed Web of Science ®Google Scholar
• Wang Y, Fan Y, Zheng C, Zhang X. 2017. Knockdown of AQP1 inhibits growth and invasion of human ovarian cancer cells. Mol Med Rep. 16:5499–5504.
   PubMed Web of Science ®Google Scholar
• Wu ZH, Tang Y, Zhou Y. 2021. Alternative splicing events implicated in carcinogenesis and prognosis of thyroid gland cancer. Sci Rep. 11:4841.
   PubMed Web of Science ®Google Scholar
• Yae T, Tsuchihashi K, Ishimoto T, Motohara T, Yoshikawa M, Yoshida GJ, Wada T, Masuko T, Mogushi K, Tanaka H, et al. 2012. Alternative splicing of CD44 mRNA by ESRP1 enhances lung colonization of metastatic cancer cell. Nat Commun. 3:883.
   PubMed Web of Science ®Google Scholar
• Yan JQ, Liu M, Ma YL, Le KD, Dong B, Li GH. 2021. Development of alternative splicing signature in lung squamous cell carcinoma. Med Oncol. 38:49.
   PubMed Web of Science ®Google Scholar
• Zhang P, Zhang P, Zhou M, Jiang H, Zhang H, Shi B, Pan X, Gao H, Sun H, Li Z. 2013. Exon 4 deletion variant of epidermal growth factor receptor enhances invasiveness and cisplatin resistance in epithelial ovarian cancer. Carcinogenesis. 34:2639–2646.
   PubMed Web of Science ®Google Scholar
• Zhu J, Chen Z, Yong L. 2018. Systematic profiling of alternative splicing signature reveals prognostic predictor for ovarian cancer. Gynecol Oncol. 148:368–374.
   PubMed Web of Science ®Google Scholar